MARGOLIN, Sara et al. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncologica, [S. l.], v. 50, n. 1, p. 35–41, 2011. DOI: 10.3109/0284186X.2010.535847. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/31806. Acesso em: 21 feb. 2025.